What makes LicriEye unique

People aged 65 years have a fifty-fifty chance of being affected by a cataract – clouding of the natural eye lens. Vision can only be restored by cataract surgery where the clouded lens is removed and replaced by an artificial lens. However, currently available lenses often fail to provide accurate vision for the patient.

LicriEye has developed an artificial, re-adjustable lens which promises patients the restoration of 100 % of their vision and has the potential to improve millions of lives.

Conventional method:

Positioning an artificial lens is challenging. The lens will not deliver perfect vision if it is not perfectly positioned.
The patient therefore, may need glasses or to undergo further surgery.

LicriEye method:

With the use of a LicriEye lens, the ophthalmologist has a better chance of adjusting
the lens using a laser and restoring the patient’s proper eyesight.

Get the white paper

LicriEye would enable ophthalmologists to change the focus of the artificial lens after cataract surgery non-invasively using a laser, thus correcting potentially poor vision. Our liquid crystals expertise plays a key role here.

Contact us to get the specialized white paper to know more about cataract, its causes and the LicriEye solution.

Request the white paper

reCAPTCHA is required.

LICRIEYE

A breakthrough technology with the potential to restore proper vision for cataract patients after surgery,
which could obviate the need for glasses or additional operations!

 

Download the brochure

Medical Advisory Board

EYeu-022-Cropped_1x1

Dr. Elizabeth Yeu-Lin, MD

Dr. Elizabeth Yeu is an Assistant Professor of Ophthalmology at Eastern Virginia Medical School and is a shareholder at Virginia Eye Consultants, in Norfolk, Va. She is the Medical Director of the Virginia Surgery Center and is a member of the Board of Directors for the Virginia Eye Foundation. She is a Cornea, Cataract and Refractive Surgery specialist, who completed her residency at Rush University Medical Center and her fellowship training from the Cullen Eye Institute of the Baylor College of Medicine.

Dr. Yeu provides guidance and governance across several national medical boards and committees. She is currently the Advisor to the Young Eye Surgeons (YES) Clinical Committee of the American Society of Cataract and Refractive Surgery (ASCRS), and is the Chair of the Cataract Section of Ophthalmic News & Education (ONE) Network for the American Ophthalmology (AAO).

Dr. Yeu has authored numerous articles and is a frequent lecturer nationally and internationally in the areas of refractive cataract surgery, anterior segment reconstruction, ocular surface disease management and surgical management of astigmatism. She is the editor-In-chief of U.S. Ophthalmic Review and served as the medical editor of the digital journal, Millennial Eye from 2015-2017.

Oliver-Findl_cropped_1x1

Prof. Dr. Oliver Findl, MD, MBA

Dr. Oliver Findl, is Professor of Ophthalmology and chairs the Department of Ophthalmology at the Hanusch Hospital, Vienna, Austria. He founded and heads the Vienna Institute for Research in Ocular Surgery (VIROS).

A research fellowship at Children’s Hospital in Boston was followed by residency and an anterior segment surgery fellowship at the Medical University of Vienna. He was a Consultant Ophthalmic Surgeon at Moorfields Eye Hospital, London for several years.

His research interests are in the fields of posterior capsule opacification, optical biometry and the pathogenesis of myopia. He has authored over 250 articles in international peer-reviewed journals and is currently the secretary of the European Society of Cataract and Refractive Surgeons (ESCRS) as well as the treasurer of the Austrian Ophthalmological Society.

EJH-PIC-2018_Cropped_1x1

Prof. Dr. Edward Holland, MD

Dr. Holland is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota and was granted the Elias Potter Lyon Chair in Ophthalmology. Dr. Holland also served as President of the Minnesota Academy of Ophthalmology.

Dr. Holland formerly served as the President for the American Society of Cataract and Refractive Surgery from 2011-2012. He was also a member of the Executive Committee and now serves as the Program Chair. He was former member of the Board of Trustees for the American Academy of Ophthalmology and was awarded their Life Achievement Honor Award.

Dr. Holland has a national and international reputation for his knowledge and expertise in the field of cornea and external disease. Dr. Holland is the author of over 270 articles in peer review journals and has edited Cornea, the most widely read textbook on corneal disease and surgery.

Our Innovation Center

We know how important and life-changing great ideas can be. Our Innovation Center was built to facilitate innovations and bring them to life, right in the heart of our headquarters in Darmstadt. It provides the perfect surrounding to try out new things and find clever solutions for today’s challenges.

In addition to our global research and development efforts, the Innovation Center is our way of shaping the future. Bringing together people, technologies and skills from different areas under one roof, it is the place where innovative ideas and projects are born and grow.

These make way for new products and services and open up exciting opportunities across all our business sectors. The Innovation Center is both a physical space and a culture of openness and exchange between employees, experimental startups, visionaries and companies around the globe. It’s a holistic approach grounded in various initiatives, events, and opportunit-ies to get involved.

Click here to learn more about Merck KGaA, Darmstadt, Germany.

Follow us!

YouTube

Contact us

reCAPTCHA is required.

This website provides information about a future product being developed by Merck KGaA, Darmstadt, Germany.
LicriEye is a patented technology, which is currently not commercially available on the worldwide market.

All our website visitors are subject to the Privacy Policy, and agree to be bound by Terms Of Use.

vibrant_m@2x